Xenon Pharmaceuticals - XENE Stock Forecast, Price & News

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Trading Down 0.8 %

NASDAQ:XENE traded down $0.30 during mid-day trading on Tuesday, hitting $39.35. The stock had a trading volume of 380,131 shares, compared to its average volume of 484,311. The stock has a 50-day simple moving average of $31.95 and a two-hundred day simple moving average of $30.79. The company has a market capitalization of $2.09 billion, a PE ratio of -21.98 and a beta of 1.53. Xenon Pharmaceuticals has a twelve month low of $14.65 and a twelve month high of $40.34.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Rating) last issued its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.03. The firm had revenue of $8.77 million for the quarter, compared to analysts' expectations of $9.22 million. Xenon Pharmaceuticals had a negative net margin of 360.80% and a negative return on equity of 20.94%. During the same quarter last year, the company earned ($0.42) earnings per share. Sell-side analysts predict that Xenon Pharmaceuticals will post -2.07 EPS for the current fiscal year.

Analyst Ratings Changes

XENE has been the subject of several research analyst reports. StockNews.com raised shares of Xenon Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Tuesday. Wedbush reduced their price target on shares of Xenon Pharmaceuticals from $47.00 to $41.00 and set an "outperform" rating on the stock in a research report on Monday, June 27th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Xenon Pharmaceuticals in a research report on Thursday, July 21st. They set an "overweight" rating and a $55.00 price target on the stock. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $45.33.